187 related articles for article (PubMed ID: 20624238)
1. Response to heat pain stimulation in idiopathic Parkinson's disease.
Nandhagopal R; Troiano AR; Mak E; Schulzer M; Bushnell MC; Stoessl AJ
Pain Med; 2010 Jun; 11(6):834-40. PubMed ID: 20624238
[TBL] [Abstract][Full Text] [Related]
2. Pain intensity on and off levodopa in patients with Parkinson's disease.
Nebe A; Ebersbach G
Mov Disord; 2009 Jun; 24(8):1233-7. PubMed ID: 19412949
[TBL] [Abstract][Full Text] [Related]
3. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.
Brefel-Courbon C; Payoux P; Thalamas C; Ory F; Quelven I; Chollet F; Montastruc JL; Rascol O
Mov Disord; 2005 Dec; 20(12):1557-63. PubMed ID: 16078219
[TBL] [Abstract][Full Text] [Related]
4. Thermal and mechanical pain thresholds in patients with fluctuating Parkinson's disease.
Vela L; Cano-de-la-Cuerda R; Fil A; Muñoz-Hellín E; Ortíz-Gutiérrez R; Macías-Macías Y; Fernández-de-Las-Peñas C
Parkinsonism Relat Disord; 2012 Sep; 18(8):953-7. PubMed ID: 22658653
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
6. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
[TBL] [Abstract][Full Text] [Related]
7. Neurophysiologic study of central pain in patients with Parkinson disease.
Schestatsky P; Kumru H; Valls-Solé J; Valldeoriola F; Marti MJ; Tolosa E; Chaves ML
Neurology; 2007 Dec; 69(23):2162-9. PubMed ID: 18056580
[TBL] [Abstract][Full Text] [Related]
8. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
Winge K; Werdelin LM; Nielsen KK; Stimpel H
Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
10. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
Stacy M; Bowron A; Guttman M; Hauser R; Hughes K; Larsen JP; LeWitt P; Oertel W; Quinn N; Sethi K; Stocchi F
Mov Disord; 2005 Jun; 20(6):726-33. PubMed ID: 15719426
[TBL] [Abstract][Full Text] [Related]
11. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
Mongeon D; Blanchet P; Messier J
Neuroscience; 2009 Jan; 158(2):426-40. PubMed ID: 18996173
[TBL] [Abstract][Full Text] [Related]
12. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
13. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
14. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?
Lim SY; Farrell MJ; Gibson SJ; Helme RD; Lang AE; Evans AH
Mov Disord; 2008 Sep; 23(12):1689-95. PubMed ID: 18709675
[TBL] [Abstract][Full Text] [Related]
15. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
Yamada K; Goto S; Hamasaki T; Kuratsu JI
Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease.
Shin HW; Kang SY; Sohn YH
Mov Disord; 2005 Dec; 20(12):1640-3. PubMed ID: 16092109
[TBL] [Abstract][Full Text] [Related]
18. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.
Limousin P; Krack P; Pollak P; Benazzouz A; Ardouin C; Hoffmann D; Benabid AL
N Engl J Med; 1998 Oct; 339(16):1105-11. PubMed ID: 9770557
[TBL] [Abstract][Full Text] [Related]
19. Multisensory determinants of orientation perception in Parkinson's disease.
Barnett-Cowan M; Dyde RT; Fox SH; Moro E; Hutchison WD; Harris LR
Neuroscience; 2010 Jun; 167(4):1138-50. PubMed ID: 20206672
[TBL] [Abstract][Full Text] [Related]
20. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
